| Ytd | 13.29% | |
| 1y | -8.19% |
| Open | 46.55 | Prev Close | 46.59 | Low | 46.59 | High | 47.43 | Mkt Cap | 1.61B |
| Vol | 89.60K | Avg Vol | 92.52K | EPS | 3.60 | P/E | 13.17 | Forward P/E | 18.89 |
| Beta | 1.01 | Short Ratio | 2.51 | Inst. Own | 50.34% | Dividend | 3.06 | Div Yield | 6.57 |
| Ex Div Date | 05-11 | Earning | 08-06 | 50-d Avg | 47.59 | 200-d Avg | 46.06 | 1yr Est | 45.50 |
GLP News
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified wa
Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansion
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the M
Eli Lilly could capitalize on the growing GLP-1 market and deliver strong returns through 2031. Howe
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) today announced that it i
Citi has said Novo Nordisk's (NYSE:NVO) Wegovy pill is outpacing its rivals in the United States, ev
CVS Health announced a program to help patients get easier access to GLP-1 medicines. This initiativ
We also report on a potentially simple solution to nausea experienced by cancer patients receiving
Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (t
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is supporting the more than 56 million patients in the M